A dedicated phase 2a substudy in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) used MRI to measure liver fat and found that, after 24 weeks, retatrutide reduced relative liver-fat content by about 81% at the 8 mg dose and about 82% at 12 mg, versus essentially no change on placebo
Procedure & Treatment Process How is chelation therapy administered
Shel Wellness & Aesthetic Center, we believe in empowering our patients with knowledge
This biological mechanism facilitates improved glycemic control and appetite regulation, contributing to sustainable weight management outcomes
Reference: Book An Appointment Now Click below to get started and schedule your appointment online
Products are intended solely for analytical, in vitro, ex vivo, or other controlled research applications